Fig 1.
Flow diagram of the study.
Table 1.
Baseline Demographic and Clinical Characteristics of the Participants.
Table 2.
Primary and Secondary Endpoints.
Fig 2.
Change in monthly migraine days (MMD) by subgroup.
Change in number of monthly migraine days (MMD) from baseline to the final 28 days of the treatment period for the entire group, participants with episodic migraine, and participants with chronic migraine. Medians, percentiles, minimums, and maximums are presented. * p < 0.05.
Fig 3.
The proportion of participants achieving≥ 50% reduction in monthly migraine days (MMD).
Percentage of participants achieving a ≥ 50% reduction in monthly migraine days (MMD) in the entire group of participants, in participants with episodic migraine and in participants with chronic migraine.
Fig 4.
Patients’ Global Impression of Change (PGIC).
Patients’ Global Impression of Change (PGIC) in the entire group of participants, in participants with episodic migraine and in participants with chronic migraine. Medians, percentiles, minimums, and maximums are presented. * p < 0.05.
Table 3.
Adverse Events Reported during the Treatment Phase.